The four UCLA CTSI partner institutions—UCLA, Cedars-Sinai Medical Center, Charles Drew University of Medicine and Science and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center— have established a process for relying on one another’s IRB for the review and oversight of certain human subjects research projects. This process allows for a single Reviewing IRB to review and approve a study that will be conducted at two or more of the partnering institutions. The primary goal of this Reliance IRB Review Process is to streamline IRB reviews of translational research conducted among the partners.
This process does not apply to ancillary committees. When applicable, approval from such ancillary committees as the Cancer Center Protocol Review and Monitoring Committee, Conflict of Interest Committee, Radiation Safety Committee, Institutional Biosafety Committee and Privacy Board will still be required by each institution.
Research studies that may take advantage of this process include both minimal risk studies that qualify for expedited review and studies that require review during a convened IRB meeting. Studies that are exempt from IRB review would not be appropriate for the Reliance IRB Review process. Protocols should be collaborations between or among any of the four Institutions and involve:
The Lead PI is responsible for submitting the new study application, amendments, continuing review reports, and post-approval reportable events to the Reviewing IRB. The other investigators will request that his/her local IRB rely on the review and approval of the Reviewing IRB.
A Reviewing IRB Decision Tree has been created to assist with decisions regarding which IRB should serve as the Reviewing IRB. Note that this determination will ultimately be made with concurrence from IRB administrators at each of the participating institutions and not solely by the investigators.
Instructions for requesting a single IRB Reliance Review for multi-institutional collaborative research can be found in the document entitled CTSI IRB Protocol Submission and Review Procedures. In general, the request starts with the submission of a completed CTSI Protocol Registration (CPR) Notice by the Lead PI to the Reviewing IRB.
The online Institutional Review Board application system, webIRB, is available to all UCLA Investigators and Study Staff. For questions or assistance, contact:
The OHRPP Office
Office of the Human Research Protection Program (OHRPP)
11000 Kinross Avenue, Suite 102
Box 951694
Los Angeles, CA 90095-1694
Campus Mail Code: 169407
| Email: | North & South General Institutional Review Boards (GC-IRB) |
| |
The Medical Institutional Review Boards 1,2, & 3 (M-IRB) |
Training sessions are being held on the South campus and in the Kinross Building. Click here to schedule a training session.
To subscribe to the webIRB listserv: Send an e-mail to: webIRB-subscribe@lists.ucla.edu. The subject line and body of the e-mail can be blank.
Click here to go to the iRIS IRB System. You will need to log-in. For more information, contact:
Office of Compliance and Regulatory Affairs
Los Angeles Biomedical Research Institute
at Harbor-UCLA Medical Center
1124 West Carson St
Torrance, CA 90502
Phone: (310) 222-3624
Cick http://cshswbweb.csmc.edu/Cedars to go to the Cedars-Sinai Webridge IRB system. For more information, contact:
Office of Research Compliance and Quality Improvement
Cedars-Sinai Medical Center
8383 Wilshire Blvd., Suite 742
Beverly Hills, CA 90211
Phone: (310) 423-3783
Email: irb@cshs.org
Click here to go to Charles Drew's IRB for more information on the IRB for Charles Drew University and their Clinical and Translational Research Center. If you have any questions regarding the IRB functions and review process, contact:
Office for the Protection of Human Subjects
Charles R. Drew University of Medicine and Science
1731 East 120th Street, Building F
Los Angeles, CA 90059
Phone: (323) 563-5902
Email: irb@cdrewu.edu
